Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB221 plus capecitabine in HER2-positive advanced breast cancer
CTR20160389Phase 3Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of coprelotamab in breast cancer, sponsored by Jacobio Pharmaceuticals. Started Sep 2016; status: active.
02
Drugs
coprelotamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20160389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160389.